Patients with chronic rhinosinusitis with nasal polyposis who are a candidate for a biologic therapy to control the inflammation within the sinuses may be eligible for a clinical trial at the Department of Otolaryngology-Head & Neck Surgery at the University of Pittsburgh under co-PIs Dr. Eric Wang, MD, FACS, Chief, Division of Rhinology and Dr. Garret Choby, MD, Associate Professor, Departments of Otolaryngology-Head & Neck Surgery and Neurological Surgery.
Patients will receive mepolizumab (brand name Nucala), an FDA-approved biologic therapy that blocks IL-5 with a self-administered shot once a month. They will be followed over 12 months with surveys every three months of quality of life, as well as repeated endoscopic findings.
Outcome measures include reducing polyp burden, improvement in sense of smell, and overall quality of life. Mepolizumab is also indicated for asthma; patients will concurrently be followed for asthma measures.
Interested patients should contact Lauren Sipe, RN, at sipel@upmc.edu or 412-647-4258.